A Review of the Cytokine IL-17 in Ocular Surface and Corneal Disease

Aim: To investigate the role of interleukin-17 in ocular surface and corneal disease. Ocular surface and corneal disease is a leading cause of blindness and is an ongoing challenge for the public health sector to implement effective therapies. The majority of cells in corneal lesions are derived pri...

Full description

Saved in:
Bibliographic Details
Published in:Current eye research 2019-01, Vol.44 (1), p.1-10
Main Authors: Garbutcheon-Singh, K. B., Carnt, N., Pattamatta, U., Samarawickrama, C., White, A., Calder, V.
Format: Article
Language:English
Subjects:
Animals
bacterial
Corneal Diseases - metabolism
dry eye
Eye Diseases - metabolism
fungal
herpes simplex
Humans
Interleukin-17 - metabolism
Keratitis
ocular surface and corneal disease
viral Acanthamoeba
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: To investigate the role of interleukin-17 in ocular surface and corneal disease. Ocular surface and corneal disease is a leading cause of blindness and is an ongoing challenge for the public health sector to implement effective therapies. The majority of cells in corneal lesions are derived primarily from neutrophils that induce inflammatory events that lead to tissue damage. One of the key pro-inflammatory cytokines is IL-17, and it has been investigated in order to facilitate the understanding of the pathogenesis of ocular surface lesion development. Method: A review of the literature was performed through a systematic approach. Results: IL-17 has been shown to exacerbate dry eye disease, viral and bacterial keratitis lesion severity, although it was found to be protective for Acanthamoeba. Antibodies developed to neutralize IL-17 have shown some promise in reducing the severity of some diseases. Conclusion: IL-17 plays a role in the pathogenesis of ocular surface and corneal disease and targeting this cytokine may provide a useful treatment option in the future.
ISSN:0271-3683
1460-2202
DOI:10.1080/02713683.2018.1519834